Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) EPS (Weighted Average and Diluted) (2016 - 2025)

Cytokinetics (CYTK) has disclosed EPS (Weighted Average and Diluted) for 10 consecutive years, with -$2.54 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) changed N/A to -$2.54 in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.75, a N/A change, with the full-year FY2025 number at -$6.54, down 24.33% from a year prior.
  • EPS (Weighted Average and Diluted) was -$2.54 for Q4 2025 at Cytokinetics, roughly flat from -$2.55 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.23 in Q2 2022 to a low of -$1362.0 in Q3 2024.
  • A 5-year average of -$129.56 and a median of -$1.36 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 99.97% in 2022, then plummeted 100789.98% in 2024.
  • Cytokinetics' EPS (Weighted Average and Diluted) stood at -$0.32 in 2021, then tumbled by 362.5% to -$1.48 in 2022, then rose by 6.76% to -$1.38 in 2023, then tumbled by 98596.72% to -$1362.0 in 2024, then skyrocketed by 99.81% to -$2.54 in 2025.
  • Per Business Quant, the three most recent readings for CYTK's EPS (Weighted Average and Diluted) are -$2.54 (Q4 2025), -$2.55 (Q3 2025), and -$1.36 (Q1 2025).